These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16014541)

  • 1. Antibodies against erythropoietin and other protein-based therapeutics: an overview.
    Kromminga A; Schellekens H
    Ann N Y Acad Sci; 2005 Jun; 1050():257-65. PubMed ID: 16014541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples.
    Mason S; La S; Mytych D; Swanson SJ; Ferbas J
    Curr Med Res Opin; 2003; 19(7):651-9. PubMed ID: 14606989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics.
    Gupta S; Indelicato SR; Jethwa V; Kawabata T; Kelley M; Mire-Sluis AR; Richards SM; Rup B; Shores E; Swanson SJ; Wakshull E
    J Immunol Methods; 2007 Apr; 321(1-2):1-18. PubMed ID: 17307199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimizing the immunogenicity of protein therapeutics.
    Chirino AJ; Ary ML; Marshall SA
    Drug Discov Today; 2004 Jan; 9(2):82-90. PubMed ID: 15012932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of protein therapeutics.
    De Groot AS; Scott DW
    Trends Immunol; 2007 Nov; 28(11):482-90. PubMed ID: 17964218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A non-radioactive method for detecting neutralizing antibodies against therapeutic proteins in serum.
    Wala I; Swanson SJ; Jing S
    J Pharm Biomed Anal; 2007 Nov; 45(4):583-9. PubMed ID: 17923367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA.
    Smith HW; Butterfield A; Sun D
    Regul Toxicol Pharmacol; 2007 Dec; 49(3):230-7. PubMed ID: 17869396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological mechanism underlying the immune response to recombinant human protein therapeutics.
    Sauerborn M; Brinks V; Jiskoot W; Schellekens H
    Trends Pharmacol Sci; 2010 Feb; 31(2):53-9. PubMed ID: 19963283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for preclinical immunogenicity assessment of protein therapeutics.
    Stas P; Lasters I
    IDrugs; 2009 Mar; 12(3):169-73. PubMed ID: 19333897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The implications of immunogenicity for protein-based multiple sclerosis therapies.
    Cohen BA; Oger J; Gagnon A; Giovannoni G
    J Neurol Sci; 2008 Dec; 275(1-2):7-17. PubMed ID: 18822434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing specificity for immunogenicity assays.
    Swanson SJ; Chirmule N
    Bioanalysis; 2009 Jun; 1(3):611-7. PubMed ID: 21083156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current methods for detecting antibodies against erythropoietin and other recombinant proteins.
    Thorpe R; Swanson SJ
    Clin Diagn Lab Immunol; 2005 Jan; 12(1):28-39. PubMed ID: 15642981
    [No Abstract]   [Full Text] [Related]  

  • 13. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.
    Mire-Sluis AR; Barrett YC; Devanarayan V; Koren E; Liu H; Maia M; Parish T; Scott G; Shankar G; Shores E; Swanson SJ; Taniguchi G; Wierda D; Zuckerman LA
    J Immunol Methods; 2004 Jun; 289(1-2):1-16. PubMed ID: 15251407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of anti-EPO antibodies in human sera by a bridging ELISA is much more sensitive when coating biotinylated rhEPO to streptavidin rather than using direct coating of rhEPO.
    Gross J; Moller R; Henke W; Hoesel W
    J Immunol Methods; 2006 Jun; 313(1-2):176-82. PubMed ID: 16740273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
    Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
    J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry.
    Neubert H; Grace C; Rumpel K; James I
    Anal Chem; 2008 Sep; 80(18):6907-14. PubMed ID: 18702532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel method for detecting neutralizing antibodies against therapeutic proteins by measuring gene expression.
    Yu Y; Piddington C; Fitzpatrick D; Twomey B; Xu R; Swanson SJ; Jing S
    J Immunol Methods; 2006 Oct; 316(1-2):8-17. PubMed ID: 16989855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and optimization of neutralizing antibody assays to monitor clinical immunogenicity.
    Civoli F; Kroenke MA; Reynhardt K; Zhuang Y; Kaliyaperumal A; Gupta S
    Bioanalysis; 2012 Nov; 4(22):2725-35. PubMed ID: 23210655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and removal of immunogenicity in therapeutic proteins.
    Baker MP; Jones TD
    Curr Opin Drug Discov Devel; 2007 Mar; 10(2):219-27. PubMed ID: 17436557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals.
    Wadhwa M; Gaines-Das R; Thorpe R; Mire-Sluis A
    Dev Biol (Basel); 2005; 122():155-70. PubMed ID: 16375260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.